Recombinant MVA-prime elicits neutralizing antibody responses by inducing antigen-specific B cells in the germinal center.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
25 Jan 2021
25 Jan 2021
Historique:
received:
30
07
2020
accepted:
07
12
2020
entrez:
26
1
2021
pubmed:
27
1
2021
medline:
27
1
2021
Statut:
epublish
Résumé
The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding antibody and CD4+ T-cell responses. This trial also showed that a vector-prime protein boost combined vaccine strategy was better than when used alone. Here we have studied three different priming vectors-plasmid DNA, recombinant MVA, and recombinant VSV, all encoding clade C transmitted/founder Env 1086 C gp140, for priming three groups of six non-human primates each, followed by a protein boost with adjuvanted 1086 C gp120 protein. Our data showed that MVA-priming favors the development of higher antibody binding titers and neutralizing activity compared with other vectors. Analyses of the draining lymph nodes revealed that MVA-prime induced increased germinal center reactivity characterized by higher frequencies of germinal center (PNA
Identifiants
pubmed: 33495459
doi: 10.1038/s41541-020-00277-1
pii: 10.1038/s41541-020-00277-1
pmc: PMC7835239
doi:
Types de publication
Journal Article
Langues
eng
Pagination
15Subventions
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : UM1-AI-100645
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : P30-AI060354
Organisme : U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
ID : OD011103
Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : OPP1032325
Références
Science. 2014 Aug 29;345(6200):1058-62
pubmed: 25170154
Science. 2015 Aug 7;349(6248):643-6
pubmed: 26184917
J Virol. 2007 Aug;81(16):8563-70
pubmed: 17553898
Immunity. 2017 Jun 20;46(6):1045-1058.e6
pubmed: 28636954
J Exp Med. 2014 Apr 7;211(4):643-51
pubmed: 24663215
Nat Med. 2010 Mar;16(3):324-8
pubmed: 20173754
Sci Transl Med. 2015 Jul 29;7(298):298ra120
pubmed: 26223303
J Virol. 2013 Jun;87(12):6986-99
pubmed: 23596289
Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11088-93
pubmed: 15258286
Vaccine. 2009 Dec 10;28(1):79-89
pubmed: 19819211
J Infect Dis. 2018 Mar 28;217(8):1280-1288
pubmed: 29325070
Immunity. 2011 Jan 28;34(1):108-21
pubmed: 21215658
Lancet. 2018 Jul 21;392(10143):232-243
pubmed: 30047376
Proc Natl Acad Sci U S A. 2009 May 12;106(19):7962-7
pubmed: 19416838
Nature. 2015 Apr 30;520(7549):688-691
pubmed: 25853476
J Immunol. 2007 Oct 15;179(8):5099-108
pubmed: 17911595
J Infect Dis. 2012 Aug 1;206(3):431-41
pubmed: 22634875
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7
pubmed: 26908875
Annu Rev Immunol. 2011;29:621-63
pubmed: 21314428
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
Immunity. 2011 Nov 23;35(5):671-80
pubmed: 22118524
Nat Commun. 2017 Nov 23;8(1):1732
pubmed: 29170366
Immunol Cell Biol. 2009 Nov-Dec;87(8):590-600
pubmed: 19721453
Nat Immunol. 2016 Oct;17(10):1197-1205
pubmed: 27573866
J Exp Med. 2009 Nov 23;206(12):2593-601
pubmed: 19917776
J Immunol. 2016 Sep 1;197(5):1832-42
pubmed: 27481845
J Virol. 2009 Sep;83(17):8300-14
pubmed: 19439471
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
N Engl J Med. 2013 Nov 28;369(22):2083-92
pubmed: 24099601
J Infect Dis. 2004 Aug 15;190(4):702-6
pubmed: 15272397
J Clin Invest. 2012 Sep;122(9):3281-94
pubmed: 22922258
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3877-82
pubmed: 19237568
Cell Rep. 2020 Jan 7;30(1):137-152.e5
pubmed: 31914381
Nature. 2014 May 29;509(7502):637-40
pubmed: 24805232
Nat Med. 2010 Mar;16(3):319-23
pubmed: 20173752
J Virol. 2002 Jun;76(11):5357-68
pubmed: 11991964
Curr Opin HIV AIDS. 2010 Sep;5(5):428-34
pubmed: 20978385
Lancet. 2008 Nov 29;372(9653):1881-1893
pubmed: 19012954
J Virol. 2013 Apr;87(8):4185-201
pubmed: 23365441
J Infect Dis. 2006 Dec 15;194(12):1661-71
pubmed: 17109337
Lancet Infect Dis. 2011 Jul;11(7):507-15
pubmed: 21570355
Arthritis Rheumatol. 2015 Mar;67(3):773-84
pubmed: 25385309
J Immunol. 2012 May 15;188(10):5166-76
pubmed: 22529301
PLoS Pathog. 2014 Jan 30;10(1):e1003853
pubmed: 24497824
J Virol. 2014 Jul;88(14):7715-26
pubmed: 24807721
Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81
pubmed: 7753828
Immunity. 2013 Mar 21;38(3):596-605
pubmed: 23499493
Lancet HIV. 2018 Jul;5(7):e366-e378
pubmed: 29898870
Nat Med. 2020 Apr;26(4):498-501
pubmed: 32235883
Curr Protoc Immunol. 2005 Jan;Chapter 12:Unit 12.11
pubmed: 18432938